December 2022 Top Biopharma Deal: Akeso – Summit for Cancer Drug Ivonescimab
December 2022 Top Biopharma Deal Upfront
Akeso development and commercialization deal with Summit for ivonescimab
Highlighted Deal Financial Comps
Date Announced:
December 5, 2022
Total Deal Value:
$5,000M
Upfront Cash:
$500M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
$4,500M dev. and sales milestones
Royalties:
Undisclosed, low double-digit royalty
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Ivonescimab (AK112 in China and Australia; SMT112 in the U.S., Canada, Europe, and Japan)
Deal Structure:
Development and Commercial License
Partnership Features:
Collaborative Development, No Shared Cost
Deal Details:
- Akeso granted Summit exclusive rights to develop and commercialize Akeso’s PD-1 / VEGF bispecific antibody ivonescimab for the treatment of cancer including non-small cell lung cancer (NSCLC) in the U.S., Canada, Europe, and Japan. Akeso will retain rights to ivonescimab for the rest of the world, including China.POINT will be responsible for the funding, development, and manufacturing of PNT2002 and PNT2003 while Lantheus will be responsible for NDA approval and development and commercial expenses.
- Summit signed a supply agreement to purchase certain drug substances for clinical and commercial use.
- Akeso will receive $500M up front ($300M within 15 days or expiry of waiting periods and $200M within 90 days) and is eligible for up to $4.5B in regulatory and commercial milestones, plus low double-digit royalties.
Last Month:
Congrats to Akeso and Summit for landing DealForma’s Dec. 2022 top biopharma deal. Last month’s Deal of the Month was POINT – Lantheus for cancer drugs PNT2002 and PNT2003. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...